PACB

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,772 of 2,925

Why it scores 18Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$39.01M

Quarter to Jun 30

Net income

$-44.74M

Quarter to Jun 30

Free cash flow

$-37.14M

Quarter to Jun 30

Operating margin

-114.4%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$320.82M total
BlackRock, Inc.
$54.33M+28.0%
ARK Investment Management LLC
$50.03M-17.9%
SOFTBANK GROUP CORP.
$34.36M0.0%
VANGUARD CAPITAL MANAGEMENT LLC
$22.51M+4.9%
GEODE CAPITAL MANAGEMENT, LLC
$12.78M+9.0%
Sumitomo Mitsui Trust Holdings, Inc.
$10.10M-14.6%
Nikko Asset Management Americas, Inc.
$10.04M-14.6%
STATE STREET CORP
$10.01M-2.6%
Point72 Asset Management, L.P.
$8.04M+1575.6%
TWO SIGMA INVESTMENTS, LP
$7.13M+20.9%
D. E. Shaw & Co., Inc.
$7.07M+15.7%
MILLENNIUM MANAGEMENT LLC
$6.66M-19.0%
GOLDMAN SACHS GROUP INC
$5.43M+226.8%
CITADEL ADVISORS LLC
$4.78M+80.6%
VANGUARD PORTFOLIO MANAGEMENT LLC
$4.49M-6.8%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$4.46M+10.3%
NORTHERN TRUST CORP
$3.95M+10.4%
VANGUARD FIDUCIARY TRUST CO
$3.68M+10.1%
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$3.58M+23.9%
Longaeva Partners L.P.
$3.56MNew
IQ EQ FUND MANAGEMENT (IRELAND) Ltd
$2.85M-5.2%
Birchview Capital, LP
$2.27M-10.0%
BANK OF AMERICA CORP /DE/
$2.26M-19.1%
Invesco Ltd.
$2.18M-11.7%
AQR CAPITAL MANAGEMENT LLC
$2.18M+70.7%
See all 224 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Operating Margin

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/PACB

Earnings Per Share

13fpro.ai/company/PACB

Loading ratio trend…

PACB key financials by period

Reported revenue, net income and operating margin by fiscal year, from PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s annual filings on SEC EDGAR.

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$160.0M$-546.4M—
FY 2024$154.0M$-309.9M—
FY 2023$200.5M$-306.7M-166.8%
FY 2022$128.3M$-314.2M—
FY 2021$130.5M$-181.2M-161.2%
FY 2020$78.9M$29.4M-132.3%
Source: PACB filings on SEC EDGAR →

Companies similar to PACB

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

PACB insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB): stock profile, AI score and financials

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PACB at 18.1/100 on a composite quality score built from its SEC filings, placing it at rank #2,772 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (7.5) and profitability (8.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reports quarterly revenue of $39.0M, net income of $-44.7M, an operating margin of -114.4%. PACB trades on the Nasdaq exchange and files with the SEC under CIK 1299130. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PACB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PACIFIC BIOSCIENCES OF CALIFORNIA, INC. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1299130 →